Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

hidradenitis suppurativa

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

InflaRx reports positive phase 2 results for HS and CSU treatments

Topline results demonstrated treatment efficacy for both conditions

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults

The inflammatory skin disease affects approximately one in every 100 people in the US

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE

UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa

The inflammatory skin disease affects about 1% of the population in most studied countries

- PMLiVE

Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa

Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition

- PMLiVE

UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

- PMLiVE

UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links